|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wakabayashi T: Clinical trial updates for
malignant brain tumors. Rinsho Shinkeigaku. 51:853–856. 2011.In
Japanese. View Article : Google Scholar
|
|
3
|
Ostrom QT, Gittleman H, Farah P, Ondracek
A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2006–2010. Neuro Oncol1.
5(Suppl 2): ii1–ii56. 2013.
|
|
4
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohgaki H: Epidemiology of brain tumors.
Cancer Epidemiology. Springer; pp. 323–342. 2009, View Article : Google Scholar
|
|
6
|
Grossman SA, Ye X, Piantadosi S, Desideri
S, Nabors LB and Rosenfeld M: Survival of patients with newly
diagnosed glioblastoma treated with radiation and temozolomide in
research studies in the United States. Clin Cancer Res.
16:2443–2449. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ballman KV, Buckner JC, Brown PD, Giannini
C, Flynn PJ, LaPlant BR and Jaeckle KA: The relationship between
six-month progression-free survival and 12-month overall survival
end points for phase II trials in patients with glioblastoma
multiforme. Neuro Oncol. 9:29–38. 2007. View Article : Google Scholar
|
|
8
|
Grossman S, Ye X, Piantadosi S, Desideri
S, Nabors L and Rosenfeld M: Current survival statistics for
patients with newly diagnosed glioblastoma treated with radiation
and temozolomide on research studies in the United States. J Clin
Oncol. 27:20032009. View Article : Google Scholar
|
|
9
|
Zhou M, Sandercock AM, Fraser CS, Ridlova
G, Stephens E, Schenauer MR, Yokoi-Fong T, Barsky D, Leary JA,
Hershey JW, et al: Mass spectrometry reveals modularity and a
complete subunit interaction map of the eukaryotic translation
factor eIF3. Proc Natl Acad Sci USA. 105:18139–18144. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sonenberg N and Hinnebusch AG: Regulation
of translation initiation in eukaryotes: Mechanisms and biological
targets. Cell. 136:731–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li BD, Liu L, Dawson M and De Benedetti A:
Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast
carcinoma. Cancer. 79:2385–2390. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lamphear BJ, Kirchweger R, Skern T and
Rhoads RE: Mapping of functional domains in eukaryotic protein
synthesis initiation factor 4G (eIF4G) with picornaviral proteases.
Implications for cap-dependent and cap-independent translational
initiation. J Biol Chem. 270:21975–21983. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Morley SJ, McKendrick L and Bushell M:
Cleavage of translation initiation factor 4G (eIF4G) during
anti-Fas IgM-induced apoptosis does not require signalling through
the p38 mitogen-activated protein (MAP) kinase. FEBS Lett.
438:41–48. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Damoc E, Fraser CS, Zhou M, Videler H,
Mayeur GL, Hershey JW, Doudna JA, Robinson CV and Leary JA:
Structural characterization of the human eukaryotic initiation
factor 3 protein complex by mass spectrometry. Mol Cell Proteomics.
6:1135–1146. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hinnebusch AG and Lorsch JR: The mechanism
of eukaryotic translation initiation: New insights and challenges.
Cold Spring Harb Perspect Biol. 4:42012. View Article : Google Scholar
|
|
16
|
Seal SN, Schmidt A and Marcus A: Ribosome
binding to inosine-substituted mRNAs in the absence of ATP and mRNA
factors. J Biol Chem. 264:7363–7368. 1989.PubMed/NCBI
|
|
17
|
Silvera D, Formenti SC and Schneider RJ:
Translational control in cancer. Nat Rev Cancer. 10:254–266. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hershey JW: Regulation of protein
synthesis and the role of eIF3 in cancer. Braz J Med Biol Res.
43:920–930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sesen J, Cammas A, Scotland SJ, Elefterion
B, Lemarié A, Millevoi S, Mathew LK, Seva C, Toulas C, Moyal EC, et
al: Int6/eIF3e is essential for proliferation and survival of human
glioblastoma cells. Int J Mol Sci. 15:2172–2190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Emmanuel R, Weinstein S, Landesman-Milo D
and Peer D: eIF3c: A potential therapeutic target for cancer.
Cancer Lett. 336:158–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Asano K, Kinzy TG, Merrick WC and Hershey
JW: Conservation and diversity of eukaryotic translation initiation
factor eIF3. J Biol Chem. 272:1101–1109. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moldave K: Eukaryotic protein synthesis.
Annu Rev Biochem. 54:1109–1149. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rothe M, Ko Y, Albers P and Wernert N:
Eukaryotic initiation factor 3 p110 mRNA is overexpressed in
testicular seminomas. Am J Pathol. 157:1597–1604. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Scoles DR, Yong WH, Qin Y, Wawrowsky K and
Pulst SM: Schwannomin inhibits tumorigenesis through direct
interaction with the eukaryotic initiation factor subunit c
(eIF3c). Hum Mol Genet. 15:1059–1070. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song N, Wang Y, Gu XD, Chen ZY and Shi LB:
Effect of siRNA-mediated knockdown of eIF3c gene on survival of
colon cancer cells. J Zhejiang Univ Sci B. 14:451–459. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Surawicz TS, McCarthy BJ, Kupelian V,
Jukich PJ, Bruner JM and Davis FG: Descriptive epidemiology of
primary brain and CNS tumors: Results from the Central Brain Tumor
Registry of the United States, 1990–1994. Neuro Oncol. 1:14–25.
1999.
|
|
27
|
Zhang L, Pan X and Hershey JW: Individual
overexpression of five subunits of human translation initiation
factor eIF3 promotes malignant transformation of immortal
fibroblast cells. J Biol Chem. 282:5790–5800. 2007. View Article : Google Scholar
|
|
28
|
Sherr CJ: Growth factor-regulated G1
cyclins. Stem Cells. 12(Suppl 1): 47–57. 1994.PubMed/NCBI
|
